Cardiac Biomarkers Market to grow at a CAGR of 12.4% during 2026 to 2035; Driven by Rising Prevalence of Cardiovascular Diseases and Increasing Demand for Early Disease Detection

Market Hightlights

The Cardiac Biomarkers Market closed 2025 at USD 17.78 billion and enters the forecast window at USD 20.13 billion in 2026, on track to reach USD 57.64 billion by 2035 at a 12.4% CAGR. The use of cardiac biomarkers as a comprehensive diagnostic strategy for numerous cardiovascular disorders is widespread.

The market for cardiac biomarkers is primarily driven by the rising prevalence of cardiovascular diseases and lifestyle illnesses, the rise in demand for disease-specific treatments and research that use cardiac biomarkers, technological advancements in cardiac biomarkers, and supportive government initiatives to raise public awareness of cardiovascular illnesses. However, a lack of public awareness is anticipated to impede cardiac biomarkers market growth.

One of the drivers for cardiac biomarkers market share is that cardiovascular and lifestyle-related diseases are becoming more common. The leading cause of death in the world is cardiovascular disease. According to the American College of Cardiology, an American will experience a myocardial infarction every 40 seconds. Lifestyle-related illnesses like diabetes and hypertension are becoming more common.

For instance, the WHO estimates that 1.13 billion individuals worldwide have hypertension. Additionally, the number of older adults who are seriously ill needs to be monitored regularly, and their loved ones should occasionally be updated on their health.

The benefits of cardiac biomarkers in treating diseases related to a sedentary lifestyle, such as cardiovascular disease, fuel market expansion. Another reason for evolving cardiac biomarkers market trends is the rise in the demand for disease-specific therapies and studies using cardiac biomarkers.

Regional Analysis

The global market for cardiac biomarkers is divided into regions based on geography: the Americas, Europe, Asia-Pacific, and the Middle East & Africa. Due to the strong demand for cardiac biomarkers testing, the high prevalence of CVD, and the increasing awareness of cardiac diagnostics solutions, the Americas dominate the global market.

Due to modernity, increased disposable incomes, the rising affordability of cutting-edge cardiac treatments, and the rising demand for cardiac biomarkers testing devices, Asia-Pacific is expanding at the fastest CAGR. In addition, people spend more money on health due to the increased per capita disposable income of middle-class families, who comprise a significant portion of the population in Asia. During the anticipated term, this will fuel the market for cardiac biomarkers in the area.

Market Segmentation

The cardiac biomarkers market is segmented by type, application, and end-use.

Based on type, the sub-segmentation is:

• Troponins (T and I)


• Myocardial Muscle Creatine Kinase (CK-MB)


• Myoglobin


• Brain Natriuretic Peptide (BNPs) or NT proBNP


• Ischemia Modified Albumin (IMA)


• ALT/AST

Based on application, the sub-segmentation is:

• Myocardial Infarction


• Congestive Heart Failure


• Acute Coronary Syndrome


• Atherosclerosis

Key Players

The key players in the cardiac biomarkers are:

• Abbott


• Quidel Corporation


• Siemens Healthineers


• Hoffmann-La Roche Ltd.


• Danaher Corporation


• Biomérieux SA


• Bio-Rad Laboratories, Inc.


• Randox Laboratories Ltd.


• Creative Diagnostics


• Life Diagnostics